Genix Pharmaceuticals Corporation
GENX.V
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.90K | 3.00K | 2.90K | 4.20K | 8.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.90K | 3.00K | 2.90K | 4.20K | 8.10K |
| Cost of Revenue | 135.40K | 135.40K | 1.30K | 1.30K | 6.10K |
| Gross Profit | -132.30K | -132.30K | 1.70K | 2.90K | 1.80K |
| SG&A Expenses | 125.40K | 133.80K | 168.10K | 156.50K | 180.50K |
| Depreciation & Amortization | 800.00 | 800.00 | 100.70K | 202.40K | 303.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 261.60K | 270.10K | 270.20K | 360.30K | 490.40K |
| Operating Income | -258.60K | -267.00K | -267.20K | -356.00K | -482.30K |
| Income Before Tax | -86.00K | -54.20K | -2.94M | -3.01M | -3.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.09 | -0.05 | -2.94 | -3.01 | -3.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.00K | -54.20K | -2.94M | -3.01M | -3.12M |
| EBIT | -258.60K | -267.00K | -267.20K | -356.00K | -482.30K |
| EBITDA | 40.60K | 32.20K | 31.30K | -54.70K | -179.50K |
| EPS Basic | 0.00 | 0.00 | -0.05 | -0.05 | -0.05 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | -0.05 | -0.05 | -0.05 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 236.90M | 236.90M | 236.90M | 236.90M | 236.90M |
| Average Diluted Shares Outstanding | 236.90M | 236.90M | 236.90M | 236.90M | 236.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |